Therapeutic Asset Ratings

208 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Personalized Neoantigen Peptide Vaccine neoplasm	Seqker Biosciences, Inc.	P1/2	CC (41)
PF-07104091 neoplasm	Pfizer	P1/2	CC (41)
rc278 neoplasm	RemeGen Co., Ltd.	P1/2	CC (41)
Revumenib neoplasm	Syndax Pharmaceuticals	P1/2	CC (41)
ro7247669 neoplasm	Hoffmann-La Roche	P1/2	CC (41)
s-531011 neoplasm	Shionogi	P1/2	CC (41)
Shr-4375 neoplasm	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	P1/2	CC (41)
Shr-4610 neoplasm	Shanghai Shengdi Pharmaceutical Co., Ltd	P1/2	CC (41)
Shr-A2102 neoplasm	Henan Cancer Hospital	P1/2	CC (41)
soa101 neoplasm	Shine-On Biomedical Co., Ltd.	P1/2	CC (41)
Tak-853 neoplasm	Takeda	P1/2	CC (41)
White Blood Cells/Granulocytes neoplasm	Dipnarine Maharaj	P1/2	CC (41)
zl-1310 neoplasm	Zai Lab (Shanghai) Co., Ltd.	P1/2	CC (41)
al8326 neoplasm	Advenchen Laboratories Nanjing Ltd.	P1	CC (40)
Allogeneic Natural Killer Cells neoplasm	Beijing Kejing Biotechnology Co., Ltd.	P1	CC (40)
bay3547922 neoplasm	Bayer	P1	CC (40)
bay3630942 neoplasm	Bayer	P1	CC (40)
[C]-Bi 907828 Mixed With Bi 907828 neoplasm	Boehringer Ingelheim	P1	CC (40)
cft1946 neoplasm	C4 Therapeutics, Inc.	P1	CC (40)
ibr854 Solid Tumors	Imbioray (Hangzhou) Biomedicine Co., Ltd.	P1	CC (40)
ibr854 cell neoplasm	Imbioray (Hangzhou) Biomedicine Co., Ltd.	P1	CC (40)
kt-333 neoplasm	Kymera Therapeutics, Inc.	P1	CC (40)
Liraglutide Solid Tumors	Seoul Hospital	P1	CC (40)
rs-0139 neoplasm	RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S.	P1	CC (40)
ASTX 660 neoplasm	Taiho Oncology, Inc.	P1/2	C (39)

Showing 101 to 125 of 208 assets